BioSpace News Archive

The Massachusetts Biotechnology Council (MassBio) is taking the lead in fostering the next generation of life science leaders in the Bay State with Project Onramp, an internship program that matches talented students from low-income backgrounds with paid internships in the state’s vibrant life science ecosystem.

Companies are filling in the gaps and the entire area of so-called “liquid biopsies” is hot these days, with companies like Guardant Health, Karius, Freenome, Apostle and GRAIL Bio entering the market. With this backdrop, let’s look at some companies working in the same field as the now-defunct Theranos.

The U.S. Senate Finance Committee and the House Oversight Committee started hearings on Tuesday, January 29, focused on dealing with high drug prices.

Real-world evidence (RWE) or real-world data (RWD) relates to the collection of information about a drug’s safety and efficacy outside the structure of a clinical trial. Speaking yesterday, FDA Commissioner Scott Gottlieb laid out the FDA’s new framework for dealing with RWE and RWD.

Dengue fever affects as many as 400 million people annually and is caused by one of four related viruses transmitted by mosquitoes. The trial showed the vaccine was efficacious in preventing dengue fever by any of the four serotypes.

Rentschler Biopharma SE announced the appointment of Dr. Christian Hunzinger (48) as the new Senior Vice President Project Management, effective from January 15, 2019.

In a recent study published in Scientific Reports, researchers at Kanazawa University show that an artificially synthesized molecule can exhibit compatible activities to natural molecules in its biological effectiveness.

Auris Medical Holding AG announced its intention to relocate the Company’s domicile from Zug, Switzerland to Hamilton, Bermuda.

Karolinska Development’s portfolio company Umecrine Cognition announces overall results from a phase 2a study with the candidate drug GR3027 in patients with idiopathic hypersomnia.

Robert Jacks, co-founder and former chief financial officer of Symbiomix Therapeutics, has taken over the reins of Cambridge, Mass.-based Indalo Therapeutics and will help guide the company in the development of therapies for patients suffering from serious fibrotic diseases such as NASH and idiopathic pulmonary fibrosis (IPF).